文献速递脑血管病

识别皮质脊髓束病灶预测小灌注卒中结局

Identification of Corticospinal Tract Lesion for Predicting Outcome in Small Perfusion Stroke.
PubMed 文献 · Stroke · 2018-01-01

研究纳入7个中心前瞻性队列中灌注病灶<15 mL且临床适合溶栓的急性缺血性卒中患者407例,由3名神经科医生判定皮质脊髓束(CST)低灌注与梗死情况,以90天改良Rankin量表评分0~1分为优良结局。结果显示仅CST低灌注而无梗死的患者接受阿替普酶治疗与优良结局独立相关,CST梗死者阿替普酶治疗与不良结局独立相关。

要点

  • 407例灌注病灶<15 mL且临床适合溶栓患者中,312例(76.7%)达到90天优良结局。
  • CST低灌注无梗死患者:阿替普酶治疗组优良结局75.6% vs 未治疗组47.1%(OR 4.096,P=0.045)。
  • CST梗死患者:阿替普酶治疗组优良结局30.6% vs 未治疗组88.9%(OR 0.002,P=0.003)。

核心结论

  • 在灌注病灶<15 mL且临床适合溶栓的急性缺血性卒中患者中,仅CST低灌注而无CST梗死者可能从溶栓中获益,该结论需未来前瞻性研究证实。
  • 作者认为,患者选择包括评估病灶位置而非单纯病灶体积可能更为理想。

研究设计与样本

  • 研究使用前瞻性收集的队列,纳入7个中心接受溶栓评估的急性缺血性卒中患者。
  • 由3名神经科医生判定CST内低灌注与梗死的存在情况。
  • 2654例患者中407例灌注病灶<15 mL且临床适合溶栓,其中243例接受溶栓治疗。
  • 优良结局定义为90天改良Rankin量表评分0~1分。

主要发现

  • 407例患者中位美国国立卫生研究院卒中量表评分为5.0,312例(76.7%)达到优良结局。
  • 阿替普酶治疗是优良结局的独立不利因素(阿替普酶治疗组72.0% vs 未治疗组83.5%;OR 0.541;P=0.025)。
  • CST低灌注无CST梗死患者中,阿替普酶治疗是优良结局的独立有利因素(阿替普酶治疗组75.6% vs 未治疗组47.1%;OR 4.096;P=0.045)。
  • CST梗死患者中,阿替普酶治疗是优良结局的独立不利因素(阿替普酶治疗组30.6% vs 未治疗组88.9%;OR 0.002;P=0.003)。
  • 无CST低灌注也无CST梗死患者中,阿替普酶治疗不是优良结局的独立影响因素(阿替普酶治疗组80.1% vs 未治疗组87.7%;P=0.258)。

关键数值与推荐

  • 灌注病灶<15 mL且临床适合溶栓的急性缺血性卒中患者共407例,其中243例接受溶栓治疗。
  • 优良结局为90天改良Rankin量表评分0~1分,312例(76.7%)达到。
  • CST低灌注无梗死患者阿替普酶治疗组优良结局75.6% vs 未治疗组47.1%(OR 4.096;P=0.045)。
  • CST梗死患者阿替普酶治疗组优良结局30.6% vs 未治疗组88.9%(OR 0.002;P=0.003)。

临床怎么用

  • 作者认为,仅CST低灌注而无CST梗死的灌注病灶<15 mL且临床适合溶栓患者可能从溶栓中获益,该结论需未来前瞻性研究证实。
  • 作者认为,患者选择包括评估病灶位置而非单纯病灶体积可能更为理想。

局限性

  • 原文结论指出该发现需在未来前瞻性研究中证实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- Whether patients with small perfusion lesions benefit from thrombolysis remains an uncertainty. We assessed acute ischemic stroke patients with a total perfusion lesion of <15 mL and tested the hypothesis the pattern of corticospinal tract (CST) involvement might predict outcome in thrombolysis-eligible patients. Methods- We used a prospectively collected cohort of acute ischemic stroke patients being assessed for thrombolysis at 7 centers. Three neurologists categorized the presence of hypoperfusion and infarction within CST. Excellent outcome was defined as 90-day modified Rankin Scale score 0 to 1. Results- Of 2654 patients, 407 had a perfusion lesion <15 mL and were clinically eligible for thrombolysis (243 being treated). Median National Institutes of Health Stroke Scale was 5.0, and 312 (76.7%) patients achieved excellent outcome. Alteplase treatment was an independent unfavorable factor for excellent outcome (alteplase-treated 72.0% versus untreated 83.5%; odds ratio, 0.541; P=0.025). For patients with CST hypoperfusion without CST infarction, alteplase treatment was an independent favorable factor for excellent outcome (alteplase-treated 75.6% versus untreated 47.1%; odds ratio, 4.096; P=0.045). Among patients with CST infarction, alteplase treatment was an independent unfavorable factor for excellent outcome (alteplase-treated 30.6% versus untreated 88.9%; odds ratio, 0.002; P=0.003). Among patients without either CST hypoperfusion or CST infarction, alteplase treatment was not an independent influencing factor for excellent outcome (alteplase-treated 80.1% versus untreated 87.7%; P=0.258). Conclusions- Only patients with CST hypoperfusion without CST infarction among eligible acute ischemic stroke patients with small perfusion lesions could benefit from thrombolysis, which needs to be confirmed in future prospective studies. Patient selection, including an assessment of lesion location rather than purely lesion volume, may be ideal.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Zhang R, Yan S, et al. Identification of Corticospinal Tract Lesion for Predicting Outcome in Small Perfusion Stroke. Stroke. 2018. PMID: 30355191. doi:10.1161/STROKEAHA.118.021426

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。